Teva Pharmaceutical Industries Limited (TEVJF)
| Previous close | 18.25 |
| Open | 18.25 |
| Bid | 15.05 x 40000 |
| Ask | 22.77 x 40000 |
| Day's range | 18.25 - 18.25 |
| 52-week range | 8.50 - 20.00 |
| Volume | |
| Avg. volume | 101 |
| Market cap | 20.676B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.39 |
| Earnings date | 06 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Nov 2017 |
| 1y target est | N/A |
GlobeNewswireTeva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version o
Simply Wall St.Teva Pharmaceutical Industries Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Teva Pharmaceutical Industries ( NYSE:TEVA ) Second Quarter 2024 Results Key Financial Results Revenue: US$4.16b (up...
ZacksTEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.
